The global pharmacokinetics services market size was valued at USD 652.8 million in 2017 and is projected to expand at a CAGR of 8.3% during the forecast period. Poor pharmacokinetics (PK) of therapeutics is one of the key reasons for higher drug attrition. In order to reduce concerns about high drug attrition, researchers are embracing the trend of PK investigation of novel moieties at each development stage.
Furthermore, implementation of predictive preclinical pharmacokinetics/ pharmacodynamics (PK/PD) models in various stages of clinical trials is recognized as a promising way to address major bottlenecks in the pharmaceutical development process. This is primarily because PK studies enable early identification of potential challenges and thereby assist in required modifications and other development strategies to mitigate drug development challenges.
Over the past decades, PK has gained significant prominence in drug discovery. Having understood the role of pharmacokinetics in pharmaceutical development, government and regulatory bodies are undertaking focused efforts to standardize pharmacokinetic protocols.
In the past years, regulatory requirements for clinical pharmacokinetic data have been progressively evolving in order to address safety implications of the drug candidate. This factor has played a vital role in reshaping this market.
PK/PD analysis has helped in progressing drug development from preclinical studies to rapid and efficient in-man studies. Use of human in vivo as well as in vitro models for studying pharmacokinetics variability in the clinical development phase has been demonstrated for various pharmaceuticals.
Gradual evolution of drug development into sound pharmacology has prompted several companies to broaden their service portfolio to maintain their competitive edge in the market. This is evident through the presence of a large number of companies with a broad service portfolio to serve various pharmaceutical development phases.
Moreover, PK studies are interfacing other drug discovery functions, such as toxicology, clinical pharmacology, and marketing. This, in turn, has lucratively bolstered the adoption of PK services within the pharmaceutical industry.
Certain limitations pertaining to in vitro PK studies, such as inability of available experiments and protocols to predict complete interactions of target and drug candidate, are expected to hamper market growth during the forecast period.
With respect to services offered as per drug type, the market is bifurcated into small and large (biopharmaceuticals) molecules. Small-molecule pharmacokinetic services emphasize on studying molecules of smaller atomic weight and drug metabolism and amount of drug compound in urine, blood, saliva, and tissue, using chromatographic techniques in combination with spectroscopic assays.
Large-molecule pharmacokinetic techniques include measurement of proteins, peptide interactions, and mostly greater weight molecules, such as IgE antibodies. They also include immunogenicity assays, Electrochemiluminescence (ECL) assays, and vaccine potency support as well as various other assays like ELISA.
With respect to revenue generation in 2017, PK analysis for small molecules accounted for the largest share owing to high market penetration. This segment is expected to expand at a lucrative pace owing to the growing market for generics.
Although PK analysis for large molecules is estimated to hold a relatively smaller share in the pharmacokinetics services market in comparison to small molecules, this segment is anticipated to grow at a faster rate. This is majorly due to rising demand for biologics and biosimilars, which has prompted CROs to invest in broadening their PK analysis service portfolio for large moieties.
North America accounted for the largest revenue share in 2017 owing to the presence of a large number prominent pharmaceutical companies in the region. A number of strategic alliances have been observed between major U.S.-based drug manufacturers and CROs that offer PK investigation services in the region. The presence of effective regulatory structure pertaining to drug development processes including PKPD and toxicology studies in the region is one of the crucial factors enabling North America’s dominance.
Asia Pacific is estimated to be the fastest growing regional market owing to perpetual business expansion of CROs in this region. Asian countries offer low operating and manufacturing costs in comparison to developed economies. Moreover, there is a strong presence of potential subject bodies in Asia Pacific. These two factors are expected to serve as driving factors for the growth of pharmacokinetic services in Asian economies.
Some of the key service providers in the market are Evotec AG; Certara, L.P.; Pacific BioLabs; GVK Biosciences Private Limited; Shanghai Medicilon Inc.; Pharmaceutical Product Development, LLC; Charles River Laboratories International, Inc.; PAREXEL International Corporation; Eurofins Scientific, Inc.; Frontage Labs; SGS SA; LGC Limited; and Creative Bioarray.
These service providers are engaged in mutually beneficial partnerships with several prominent pharmaceutical and biopharmaceutical companies across the globe. Furthermore, these service providers are making focused efforts to meet the demand of pharmaceutical developers and enhance their market position.
Report Attribute |
Details |
Market size value in 2020 |
USD 0.85 billion |
Revenue forecast in 2025 |
USD 1.24 billion |
Growth Rate |
CAGR of 8.3% from 2018 to 2025 |
Base year for estimation |
2017 |
Historical data |
2013 - 2017 |
Forecast period |
2018 - 2025 |
Quantitative units |
Revenue in USD Million and CAGR from 2018 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Drug type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; Japan; China; India; Brazil; South Africa |
Key companies profiled |
Evotec AG; Certara, L.P.; Pacific BioLabs; Pharmaceutical Product Development, LLC; Charles River Laboratories International, Inc.; PAREXEL International Corporation; Eurofins Scientific, Inc.; Frontage Labs; SGS SA; LGC Limited; Creative Bioarray. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2013 to 2025. For the purpose of this report, Grand View Research has segmented the global pharmacokinetics services market report on the basis of drug type and region:
Drug Type Outlook (Revenue, USD Million, 2013 - 2025)
Small Molecules Pharmacokinetics Services
Large Molecules (Biopharmaceuticals) Pharmacokinetics Services
Regional Outlook (Revenue, USD Million, 2013 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
China
India
Latin America
Brazil
Middle East & Africa
South Africa
b. The global pharmacokinetics services market size was estimated at USD 0.78 billion in 2019 and is expected to reach USD 0.85 billion in 2020.
b. The global pharmacokinetics market is expected to grow at a compound annual growth rate of 8.07% from 2020 to 2025 to reach USD 1.24 billion by 2025.
b. Small molecules dominated the pharmacokinetics market with a share of 77% in 2019. This is primarily because of the high penetration of small molecules and expanding popularity of generics.
b. Some key players operating in the pharmacokinetics market include Evotec AG; Certara, L.P.; Pacific BioLabs; Pharmaceutical Product Development, LLC; Charles River Laboratories International, Inc.; PAREXEL International Corporation; Eurofins Scientific, Inc.; Frontage Labs; SGS SA; LGC Limited; and Creative Bioarray.
b. Key factors that are driving the market growth include rising concern of drug attrition rate among drug developers and significantly increase in number of candidate programs for clinical trial studies.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.